MedDay Pharmaceuticals operates in the biopharmaceutical sector, focusing on the research and development of treatments for neurodegenerative diseases. Utilizing their proprietary metabolomics platform, SPECMET, MedDay identifies specific metabolic signatures in central nervous system disorders, which aids in the development of new therapeutic solutions. The company primarily serves patients suffering from neurodegenerative conditions, healthcare providers, and research institutions. MedDay's business model revolves around the discovery and commercialization of novel drugs, generating revenue through product sales, partnerships, and licensing agreements. The market it operates in is highly specialized, targeting unmet medical needs in the neurology field. MedDay's innovative approach and strong scientific advisory board position it as a leader in neurodegenerative disease research.

Keywords: neurodegenerative diseases, metabolomics, SPECMET, central nervous system, therapeutic solutions, biopharmaceutical, drug discovery, healthcare providers, research institutions, commercialization.